Press Release Archive
(BUSINESS WIRE)--Pfizer Global Manufacturing announced today plans to reconfigure its worldwide plant network to create a fully aligned manufacturing and supply organization from the combined networks of Pfizer and Wyeth. This implementation of the first phase of Pfizer’s previously announced Plant Network Strategy includes recommendations to cease operations at eight manufacturing sites in Ireland, Puerto Rico, and the United States by the
(BUSINESS WIRE)--In a first-of-a-kind collaboration between academia and industry, Pfizer Inc. will give scientists at Washington University School of Medicine in St. Louis unprecedented access to information regarding more than 500 pharmaceuticals and pharmaceutical candidates in a partnership that focuses on discovering new uses for existing compounds. Under the five-year agreement announced today, Pfizer will provide $22.5 million
(BUSINESS WIRE)--Pfizer Animal Health announced today the first recipients of a new $2 million scholarship program for U.S. veterinary students. The initiative, designed to support the future of the veterinary profession, will provide up to $2 million in scholarships over its first three years. Administered in partnership with the American Veterinary Medical Foundation (AVMF), the program is an opportunity for Pfizer Animal Health to
BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE): First-Quarter 2010 Revenues of $16.8 Billion First-Quarter 2010 Reported Diluted EPS(1) of $0.25, Adjusted Diluted EPS(2) of $0.60 Reaffirms 2010 Financial Guidance and 2012 Diluted EPS Target Ranges Continues to Make Solid Progress on the Wyeth Integration ($ in millions, except per share
NEW YORK & WASHINGTON--(BUSINESS WIRE)--NEW YORK
(BUSINESS WIRE)--NEW YORK
(BUSINESS WIRE)--Pfizer Inc. announced today the discontinuation of the SUN 1170 Phase 3 open-label study of Sutent(r) (sunitinib malate) in advanced hepatocellular carcinoma (HCC), or liver cancer. Following a review by the independent Data Monitoring Committee (DMC), the study was discontinued based on a higher incidence of serious adverse events in the sunitinib arm compared to the sorafenib arm and the fact that sunitinib did not meet the
(BUSINESS WIRE)--The board of directors of Pfizer Inc. today declared an 18-cent second-quarter 2010 dividend on the company’s common stock, payable June 1, 2010, to shareholders of record at the close of business on May 7, 2010. The second-quarter 2010 cash dividend will be the 286th consecutive quarterly dividend paid by Pfizer. At the company’s Annual Meeting of Shareholders, Chairman and Chief Executive Officer
(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a Webcast of the Annual Meeting of Shareholders at 8:30 a.m. Eastern Daylight Time on Thursday, April 22, 2010. To access the Webcast, visit the Website at www.pfizer.com and click on the “Annual Meeting of Shareholders” Webcast link on the homepage. Information on accessing and pre-registering for the Webcast will be available at www.pfizer.com
April 15, 2010 - Stemgent and Pfizer Announce Collaboration
(BUSINESS WIRE)--BOSTON
(BUSINESS WIRE)--Pfizer Oncology announced today that it will present new data from the company’s pipeline, including two novel, dual PI3K/mTOR (phosphatidylinositol 3-kinase / mammalian target of rapamycin) inhibitors (PF-046915021 and PKI-587, also known as PF-05212384);2 crizotinib (PF-02341066), an ALK (anaplastic lymphoma kinase) inhibitor that also inhibits c-MET (c-mesenchymal-epithelial transition factor);3 and PF-04605412, an
(BUSINESS WIRE)--Pfizer Inc. and Acacia Living, Inc. (Acacia) announced today they have entered into a strategic alliance to develop an innovative holistic technology solution dedicated to helping seniors age positively and independently. Acacia Living is developing an at-home assisted living connectivity platform to support the ability of a growing aging population to live independently, by improving what Acacia calls access to C.A.
(BUSINESS WIRE)--Pfizer Inc. today released detailed information about how and why the company works with a range of healthcare professionals and researchers to advance patient care and develop lifesaving medicines. The information reflects payments or exchanges of value received by licensed U.S. healthcare professionals who consulted with Pfizer about the development and marketing of new medicines and helped to educate other healthcare
(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, May 4, 2010. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s First Quarter 2010 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web
(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced it has signed a 10-year Provisional Supply Agreement to supply Prevenar 13* (Pneumococcal Polysaccharide Conjugate Vaccine [13-valent, adsorbed]), the company’s 13-valent pneumococcal conjugate vaccine, for infants and young children in the world’s poorest countries under the terms of the Advance Market Commitment (AMC) pilot project against pneumococcal disease. The AMC is a
(BUSINESS WIRE)--Because pet owners may be even more confused this spring about how to safely use topical flea-and-tick control treatments, Pfizer Animal Health is encouraging pet owners to consult with their veterinarian, instead of attempting to manage flea-and-tick control on their own. This month, the U.S. Environmental Protection Agency (EPA) announced new actions to increase the safety of dozens of spot-on pesticide products
(BUSINESS WIRE)--According to results from a Phase III safety and immunogenicity study presented today, Prevenar 13* (Pneumococcal polysaccharide conjugate vaccine, [13-valent, adsorbed]) was shown to be immunogenic and generally well tolerated in healthy young children who had received at least three prior doses of Prevenar* (Pneumococcal Saccharide Conjugated Vaccine, Adsorbed). These data were presented today at the 7th International
(BUSINESS WIRE)--Lipitor® (atorvastatin calcium) 80 mg was associated with a significantly reduced risk of major cardiovascular events compared with Lipitor 10 mg among patients with both coronary heart disease (CHD) and chronic kidney disease (CKD) who were obese or had metabolic syndrome. These data, from two sub-analyses of the Treating to New Targets (TNT) trial that were designed and completed following the completion of TNT, were
(BUSINESS WIRE)--Pfizer Inc. announced today the discontinuation of A4021018 (also known as ADVIGO 1018), a Phase 3 trial examining the effects of investigational compound figitumumab (CP-751,871) in combination with erlotinib as a second/third-line treatment in patients with previously treated advanced non-adenocarcinoma non-small cell lung cancer (NSCLC). An independent Data Safety Monitoring Committee (DSMC) recommended A4021018 be stopped
(BUSINESS WIRE)--Pfizer Inc. announced today that two Phase 3 studies of Sutent® (sunitinib malate) in advanced breast cancer did not meet their primary endpoints. The SUN 1064 Phase 3 study of sunitinib in combination with docetaxel for the first-line treatment of patients with advanced HER-2 negative breast cancer did not show a statistically significant improvement in progression-free survival compared with docetaxel alone. In
Pages
Press release archive foot note
Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.
Stay on top of Pfizer breaking news: Get News Alerts by RSS. 
Stock Quote Disclaimer
20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.
 |
If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page. |
Current Stock Price
| . |
. . |
| %Change | . | 52 Wk. High | . |
| Day High | . | 52 Wk. Low | . |
| Day Low | . | Mkt. Cap(Bil) | . |
| Open | . | ||
| Prev Close | . | Symbol | . |
| Vol. | . | Exchange | . |
Online Pfizer Press Kit
Our press kit provides information that might help you write stories or simply find out more about Pfizer.